A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis

Abstract Immune response to biologics treatment, while widely reported, yet fails to correlate with clinical outcomes and assay to assay comparison is often not possible. Hence, we developed a new peptide based-detection assay to stratify pediatric patients with juvenile idiopathic arthritis (JIA) o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hendrik Rusche, Edoardo Marrani, Feliciana Real-Fernandez, Roberta Ponti, Francesco Terzani, Ilaria Maccora, Olivier Monasson, Maria Vincenza Mastrolia, Elisa Peroni, Ilaria Pagnini, Rolando Cimaz, Anna Maria Papini, Gabriele Simonini, Paolo Rovero
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cb1b521c419a45e9849274f9c708bf09
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb1b521c419a45e9849274f9c708bf09
record_format	dspace
spelling	oai:doaj.org-article:cb1b521c419a45e9849274f9c708bf092021-12-02T15:08:38ZA peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis10.1038/s41598-021-95920-92045-2322https://doaj.org/article/cb1b521c419a45e9849274f9c708bf092021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95920-9https://doaj.org/toc/2045-2322Abstract Immune response to biologics treatment, while widely reported, yet fails to correlate with clinical outcomes and assay to assay comparison is often not possible. Hence, we developed a new peptide based-detection assay to stratify pediatric patients with juvenile idiopathic arthritis (JIA) or chronic non-infectious uveitis (CNU) and monitor anti-drug antibodies (ADAbs) formed as part of an immune response to treatment with the fully human monoclonal therapeutic antibody Adalimumab. Adalimumab derived synthetic peptides were optimized for maximum immunogenicity and were tested by SP-ELISA on a development cohort of 18 JIA and CNU treated patients. The two best performing peptides able to differentiate patient groups were selected for evaluation with a larger scale ELISA testing on a total of 29 sera from pediatric patients with JIA or CNU. The results of this peptide-based assay were compared to an in-house developed SPR biosensor ADAbs assay and a commercially available bridging ELISA. The first peptide, termed HC3, was able to positively detect ADAbs in 7 out of the 29 sera, while the second peptide, called LC3, was able to detect ADAbs in 11 out of 29 sera in the evaluation group. Following statistical data evaluation, it has been found that the detection of ADAbs using the peptide-based ELISA assay positively correlates with disease progression and remission. Two synthetic peptides derived from Adalimumab may provide a beneficial tool to clinicians for monitoring patient response to such treatment and taking informed decisions for treatment alternatives.Hendrik RuscheEdoardo MarraniFeliciana Real-FernandezRoberta PontiFrancesco TerzaniIlaria MaccoraOlivier MonassonMaria Vincenza MastroliaElisa PeroniIlaria PagniniRolando CimazAnna Maria PapiniGabriele SimoniniPaolo RoveroNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hendrik Rusche Edoardo Marrani Feliciana Real-Fernandez Roberta Ponti Francesco Terzani Ilaria Maccora Olivier Monasson Maria Vincenza Mastrolia Elisa Peroni Ilaria Pagnini Rolando Cimaz Anna Maria Papini Gabriele Simonini Paolo Rovero A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
description	Abstract Immune response to biologics treatment, while widely reported, yet fails to correlate with clinical outcomes and assay to assay comparison is often not possible. Hence, we developed a new peptide based-detection assay to stratify pediatric patients with juvenile idiopathic arthritis (JIA) or chronic non-infectious uveitis (CNU) and monitor anti-drug antibodies (ADAbs) formed as part of an immune response to treatment with the fully human monoclonal therapeutic antibody Adalimumab. Adalimumab derived synthetic peptides were optimized for maximum immunogenicity and were tested by SP-ELISA on a development cohort of 18 JIA and CNU treated patients. The two best performing peptides able to differentiate patient groups were selected for evaluation with a larger scale ELISA testing on a total of 29 sera from pediatric patients with JIA or CNU. The results of this peptide-based assay were compared to an in-house developed SPR biosensor ADAbs assay and a commercially available bridging ELISA. The first peptide, termed HC3, was able to positively detect ADAbs in 7 out of the 29 sera, while the second peptide, called LC3, was able to detect ADAbs in 11 out of 29 sera in the evaluation group. Following statistical data evaluation, it has been found that the detection of ADAbs using the peptide-based ELISA assay positively correlates with disease progression and remission. Two synthetic peptides derived from Adalimumab may provide a beneficial tool to clinicians for monitoring patient response to such treatment and taking informed decisions for treatment alternatives.
format	article
author	Hendrik Rusche Edoardo Marrani Feliciana Real-Fernandez Roberta Ponti Francesco Terzani Ilaria Maccora Olivier Monasson Maria Vincenza Mastrolia Elisa Peroni Ilaria Pagnini Rolando Cimaz Anna Maria Papini Gabriele Simonini Paolo Rovero
author_facet	Hendrik Rusche Edoardo Marrani Feliciana Real-Fernandez Roberta Ponti Francesco Terzani Ilaria Maccora Olivier Monasson Maria Vincenza Mastrolia Elisa Peroni Ilaria Pagnini Rolando Cimaz Anna Maria Papini Gabriele Simonini Paolo Rovero
author_sort	Hendrik Rusche
title	A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
title_short	A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
title_full	A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
title_fullStr	A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
title_full_unstemmed	A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
title_sort	peptide-based anti-adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/cb1b521c419a45e9849274f9c708bf09
work_keys_str_mv	AT hendrikrusche apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT edoardomarrani apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT felicianarealfernandez apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT robertaponti apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT francescoterzani apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT ilariamaccora apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT oliviermonasson apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT mariavincenzamastrolia apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT elisaperoni apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT ilariapagnini apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT rolandocimaz apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT annamariapapini apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT gabrielesimonini apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT paolorovero apeptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT hendrikrusche peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT edoardomarrani peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT felicianarealfernandez peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT robertaponti peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT francescoterzani peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT ilariamaccora peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT oliviermonasson peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT mariavincenzamastrolia peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT elisaperoni peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT ilariapagnini peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT rolandocimaz peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT annamariapapini peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT gabrielesimonini peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis AT paolorovero peptidebasedantiadalimumabantibodyassaytomonitorimmuneresponsetobiologicstreatmentinjuvenileidiopathicarthritisandchildhoodchronicnoninfectiousuveitis
_version_	1718388087649730560

A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis

Ejemplares similares